The Potential Benefit of Beta-Blockers for the Management of COVID-19 Protocol Therapy-Induced QT Prolongation: A Literature Review
The World Health Organization (WHO) officially announced coronavirus disease 2019 (COVID-19) as a pandemic in March 2020. Unfortunately, there are still no approved drugs for either the treatment or the prevention of COVID-19. Many studies have focused on repurposing established antimalarial therapi...
Saved in:
Main Authors: | Teuku Heriansyah (Author), Indah Nur Chomsy (Author), Lyra Febrianda (Author), Tjut Farahiya Hadi (Author), Titin Andri Wihastuti (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2020-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative Characteristics of Beta-Blockers in Patients with Congenital Long QT Syndrome
by: A. Yu. Proshlyakov, et al.
Published: (2021) -
Prolonged QT During Epileptic Seizures
by: J Gordon Millichap
Published: (2010) -
Prolonged QT Syndrome Presenting as Epilepsy
by: J Gordon Millichap
Published: (1994) -
Effect of QT interval-prolonging drugs taken in pregnancy on the neonatal QT interval
by: Holger Michel, et al.
Published: (2023) -
QT PRODACT: In Vivo QT Assay in the Conscious Dog for Assessing the Potential for QT Interval Prolongation by Human Pharmaceuticals
by: Shigeki Toyoshima, et al.
Published: (2005)